发布时间：2025-11-11 10:50
INCHEON, Korea--(BUSINESS WIRE)--Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms.





Epis NexLab will focus on transforming highly scalable core technologies into platforms for the discovery of diverse new drug candidates, including license-out or joint development with global pharmaceutical companies. As part of its search for new business opportunities, the company plans to explore various new modalities including amino acid or peptide conjugate platform technologies.

Peter Seongwon Hong will serve as the Chief Executive Officer (CEO) of Epis NexLab, in addition to his current role as the Executive Vice President and Head of Research and Early Development at Samsung Bioepis. He will also serve on the board of directors of Samsung Epis Holdings as a non-executive director.


=*=*=*=*=*=
当前为第1/3页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页